Media stories about BioTelemetry (NASDAQ:BEAT) have been trending somewhat positive this week, Accern Sentiment reports. Accern scores the sentiment of press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. BioTelemetry earned a media sentiment score of 0.16 on Accern’s scale. Accern also gave news stories about the medical research company an impact score of 45.0954534825026 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
A number of analysts have issued reports on BEAT shares. Zacks Investment Research downgraded BioTelemetry from a “hold” rating to a “strong sell” rating in a report on Thursday, November 2nd. Dougherty & Co reissued a “buy” rating and issued a $40.00 target price on shares of BioTelemetry in a report on Wednesday, November 8th. BidaskClub raised BioTelemetry from a “sell” rating to a “hold” rating in a report on Wednesday, December 27th. Raymond James Financial started coverage on BioTelemetry in a report on Thursday, October 26th. They issued an “outperform” rating and a $37.00 target price for the company. Finally, SunTrust Banks started coverage on BioTelemetry in a report on Monday, October 23rd. They issued a “buy” rating and a $41.00 target price for the company. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company. BioTelemetry presently has a consensus rating of “Hold” and a consensus price target of $42.86.
Shares of BioTelemetry (NASDAQ BEAT) opened at $33.55 on Friday. BioTelemetry has a fifty-two week low of $21.60 and a fifty-two week high of $39.20. The company has a debt-to-equity ratio of 0.75, a current ratio of 1.60 and a quick ratio of 1.48. The firm has a market capitalization of $1,090.00, a PE ratio of 25.61, a PEG ratio of 1.49 and a beta of 0.53.
COPYRIGHT VIOLATION NOTICE: This report was originally posted by Ticker Report and is owned by of Ticker Report. If you are viewing this report on another publication, it was illegally copied and republished in violation of U.S. and international trademark and copyright laws. The original version of this report can be accessed at https://www.tickerreport.com/banking-finance/3148880/biotelemetry-beat-receiving-somewhat-positive-press-coverage-analysis-shows.html.
BioTelemetry, Inc (BioTelemetry), formerly CardioNet, Inc, provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The Company operates in three segments: patient services, product and research services. The patient services business segment’s principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry(MCOT), event and Holter services in a healthcare setting.
Receive News & Ratings for BioTelemetry Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry and related companies with MarketBeat.com's FREE daily email newsletter.